Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock market. From the intricate defenses of cybersecurity to the vast frontiers of space technology, and from life-saving biotechnological breakthroughs to the efficiency gains
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
New York, NY – December 3, 2025 – In a significant move reverberating through the biotechnology sector, investment banking giant Morgan Stanley has downgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from "Overweight" to "Equal-Weight." The firm maintained its price target of $767.00, signaling that, in their view, the stock is now fairly valued
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market.
But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released tomorrow, November 20, 2025. This crucial economic indicator has been delayed by a recent, record-long U.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
